80 results match your criteria: "Center for Emerging Virus Research[Affiliation]"

Chronic Hepatitis B Genotype C Mouse Model with Persistent Covalently Closed Circular DNA.

Viruses

December 2024

The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.

Hepatitis B virus (HBV) can cause chronic infections, significantly increasing the risk of death from cirrhosis and hepatocellular carcinoma (HCC). A key player in chronic HBV infection is covalently closed circular DNA (cccDNA), a stable episomal form of viral DNA that acts as a persistent reservoir in infected hepatocytes and drives continuous viral replication. Despite the development of several animal models, few adequately replicate cccDNA formation and maintenance, limiting our understanding of its dynamics and the evaluation of potential therapeutic interventions targeting cccDNA.

View Article and Find Full Text PDF

Background: Although recommended isolation periods for Coronavirus disease 2019 (COVID-19) have been shortened as the pandemic has subsided, prolonged Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) shedding remains common in immunocompromised patients. This study estimated the probability of viral clearance in these patients based on elapsed days and specific risk factors.

Methods: We prospectively enrolled immunocompromised patients with a confirmed COVID-19 diagnosis from January 2022 to May 2023 during the Omicron variant era.

View Article and Find Full Text PDF

Background: Despite the proven effectiveness of oral antivirals against severe acute respiratory syndrome coronavirus 2 in randomized trials, their clinical reevaluation is vital in the context of widespread immunity and milder prevalent variants. This study aimed to assess the effectiveness of oral antivirals for coronavirus disease 2019 (COVID-19).

Methods: This retrospective cohort study utilized a target trial emulation framework to analyze patients with COVID-19 aged 60+ from January to December 2022.

View Article and Find Full Text PDF
Article Synopsis
  • A study was conducted to evaluate the safety of COVID-19 treatments nirmatrelvir/ritonavir (NMVr) and molnupiravir (MOL) by comparing acute complications in treated versus untreated patients.
  • Data from nationwide databases were used to analyze results from over 700,000 NMVr users and over 150,000 MOL users, focusing on specific cardiac and neurological events.
  • The findings revealed that both NMVr and MOL users had a lower risk of certain serious side effects like atrial fibrillation and dysgeusia, suggesting these treatments may be effective in reducing acute complications linked to COVID-19.
View Article and Find Full Text PDF

Purpose: We assessed human papillomavirus (HPV) genotype-based risk stratification and the efficacy of cytology testing for cervical cancer screening in patients with atypical squamous cells of undetermined significance (ASCUS)/low-grade squamous intraepithelial lesion (LSIL).

Materials And Methods: Between 2010 and 2021, we monitored 1,237 HPV-positive women with ASCUS/LSIL every 6 months for up to 60 months. HPV infections were categorized as persistent (HPV positivity consistently observed post-enrollment), negative (HPV negativity consistently observed post-enrollment), or non-persistent (neither consistently positive nor negative).

View Article and Find Full Text PDF

Human immunodeficiency virus-1 (HIV-1) encodes a transcriptional factor called Tat, which is critical for viral transcription. Tat-mediated transcription is highly ordered apart from the cellular manner; therefore, it is considered a target for developing anti-HIV-1 drugs. However, drugs targeting Tat-mediated viral transcription are not yet available.

View Article and Find Full Text PDF

The host protease KLK5 primes and activates spike proteins to promote human betacoronavirus replication and lung inflammation.

Sci Signal

August 2024

Center for Study of Emerging and Re-emerging Viruses, Korea Virus Research Institute, Institute for Basic Science, Daejeon 34126, Republic of Korea.

Article Synopsis
  • Coronaviruses need host proteases, like KLK5, to activate their spike proteins, enabling them to enter host cells and release their genetic material.
  • KLK5 is particularly effective among the KLK family, as it activates spike proteins of several human betacoronaviruses, including SARS-CoV-2, while other proteases like KLK12 and KLK13 have more specialized roles.
  • The study suggests that targeting KLK5 with compounds such as ursolic acid could be a potential treatment to inhibit coronavirus replication and reduce inflammation in infected individuals.
View Article and Find Full Text PDF

Deciphering the evolutionary landscape of severe fever with thrombocytopenia syndrome virus across East Asia.

Virus Evol

July 2024

Center for Study of Emerging and Re-emerging Viruses, Korea Virus Research Institute, Institute for Basic Science (IBS), Daejeon, Republic of Korea.

Severe fever with thrombocytopenia syndrome virus (SFTSV) poses a significant public health challenge in East Asia, necessitating a deeper understanding of its evolutionary dynamics to effectively manage its spread and pathogenicity. This study provides a comprehensive analysis of the genetic diversity, recombination patterns, and selection pressures across the SFTSV genome, utilizing an extensive dataset of 2041 sequences from various hosts and regions up to November 2023. Employing maximum likelihood and Bayesian evolutionary analysis by sampling trees (BEAST), we elucidated the phylogenetic relationships among nine distinct SFTSV genotypes (A, B1, B2, B3, B4, C, D, E, and F), revealing intricate patterns of viral evolution and genotype distribution across China, South Korea, and Japan.

View Article and Find Full Text PDF

Severe fever with thrombocytopenia syndrome virus (SFTSV) or is an emerging pathogen responsible for SFTS. It is considered a novel threat to human health, given the high associated fatality. SFTSV is a segmented negative-strand RNA virus containing three single-stranded RNAs, with the M segment encoding the glycoproteins Gn and Gc.

View Article and Find Full Text PDF

Analysis of host factor networks during hepatitis B virus infection in primary human hepatocytes.

Virol J

August 2024

Division of Chronic Viral Diseases, Center for Emerging Virus Research, Korea National Institute of Health, 187 Osongsaengmyeong 2-ro, Cheongju, 363951, Korea.

Background: Chronic hepatitis B virus (HBV) infection affects around 250 million people worldwide, causing approximately 887,000 deaths annually, primarily owing to cirrhosis and hepatocellular carcinoma (HCC). The current approved treatments for chronic HBV infection, such as interferon and nucleos(t)ide analogs, have certain limitations as they cannot completely eradicate covalently closed circular DNA (cccDNA). Considering that HBV replication relies on host transcription factors, focusing on host factors in the HBV genome may provide insights into new therapeutic targets against HBV.

View Article and Find Full Text PDF
Article Synopsis
  • Genotype V (GV) Japanese encephalitis virus (JEV) has been a major concern in South Korea since 2010 due to its heightened virulence and distinct antigenic properties, leading to reduced vaccine effectiveness.
  • A clinical strain, K15P38, isolated from a patient in 2015, was obtained for research, and a new variant was identified that produces smaller plaques and possesses specific amino acid mutations in key viral proteins.
  • This newly isolated variant shows delayed growth in lab settings and a milder infection response in mice, providing valuable insights for studying GV JEV's pathology and its implications for future research.
View Article and Find Full Text PDF

Given the previous SARS-CoV-2 pandemic and the inherent unpredictability of viral antigenic drift and shift, preemptive development of diverse neutralizing antibodies targeting a broad spectrum of epitopes is essential to ensure immediate therapeutic and prophylactic interventions during emerging outbreaks. In this study, we present a monoclonal antibody engineered for cross-reactivity to both wild-type and Delta RBDs, which, surprisingly, demonstrates enhanced neutralizing activity against the Omicron variant despite a significant number of mutations. Using an inner membrane display of a human naïve antibody library, we identified antibodies specific to the wild-type SARS-CoV-2 receptor binding domain (RBD).

View Article and Find Full Text PDF
Article Synopsis
  • Researchers created a double-transgenic mouse model that expresses both human ACE2 and TMPRSS2 to study how SARS-CoV-2 infects and harms the body.* -
  • These mice exhibited severe weight loss, lung injury, and high susceptibility to the virus, making them a useful model for investigating disease mechanisms.* -
  • Treatment with the TMPRSS2 inhibitor nafamostat showed promise in reducing weight loss and virus replication, indicating potential therapeutic strategies against COVID-19.*
View Article and Find Full Text PDF

Effect of Paxlovid in COVID-19 treatment during the periods of SARS-CoV-2 Omicron BA.5 and BN.1 subvariant dominance in the Republic of Korea: a retrospective cohort study.

Osong Public Health Res Perspect

April 2024

Patient Management Team, Centrol Headquarters of COVID-19, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.

Background: This study was conducted to assess the efficacy of nirmatrelvir/ritonavir treatment in patients with coronavirus disease 2019 (COVID-19), particularly those aged 60 years and older. Using real-world data, the period during which the BN.1 Omicron variant was dominant was compared to the period dominated by the BA.

View Article and Find Full Text PDF

Background: This study evaluated the clinical characteristics of patients with COVID-19 in Korea, and examined the relationship between severe COVID-19 cases and underlying health conditions during the Delta (September 20, 2021 to December 4, 2021) and the Omicron (February 20, 2022 to March 31, 2022) predominant period.

Methods: This study assessed the association between critical COVID-19 illness and various risk factors, including a variety of underlying health conditions, using multiple logistic regression models based on the K-COV-N cohort, a nationwide data of confirmed COVID-19 cases linked with COVID-19 vaccination status and the National Health Insurance claim information.

Results: We analyzed 137,532 and 8,294,249 cases of COVID-19 infection during the Delta and the Omicron variant dominant periods, respectively.

View Article and Find Full Text PDF
Article Synopsis
  • * A study showed that while immunity against MERS-CoV declined over five years, some recovered patients had increased antibody levels during the COVID-19 pandemic, likely due to cross-reactive immunity from SARS-CoV-2 vaccinations or infections.
  • * Key immunogenic regions of CoVs, such as specific epitopes from the spike protein, showed strong immune responses during the pandemic, suggesting that targeting these regions could aid in developing a pan-CoV vaccine.
View Article and Find Full Text PDF

HPV vaccination status and effectiveness in Korean women with HPV16/18 infection (2010-2021): a retrospective study.

J Gynecol Oncol

September 2024

Division of Clinical Research, Center for Emerging Virus Research, National Institute of Infectious Diseases, Korea National Institute of Health, Cheongju, Korea.

Objective: To evaluate human papillomavirus (HPV) vaccine effectiveness in a cohort of Korean women infected with HPV.

Methods: From 2010 to 2021, Korean women aged 20-60 years who diagnosed HPV-positive atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion were recruited from 6 hospitals. HPV vaccine effectiveness was estimated by observing the differences in pathological and clinical information and experimental results-prevalence, viral load (VL), physical state (PS), and HPV16/18 infection duration-between the vaccinated and unvaccinated groups.

View Article and Find Full Text PDF

Background: Solid organ transplant recipients (SOTRs) are at higher risk for severe infection. However, the risk for severe COVID-19 and vaccine effectiveness among SOTRs remain unclear.

Methods: This retrospective study used a nationwide health care claims database and COVID-19 registry from the Republic of Korea (2020 to 2022).

View Article and Find Full Text PDF

Despite a high vaccination rate, the COVID-19 pandemic continues with immune-evading Omicron variants. The success of additional antigenic stimulation through breakthrough infection (BI) and updated vaccination in overcoming antigenic imprinting needs to be determined. Participants in a long-term follow-up cohort of healthcare worker (HCW) vaccinee were categorized according to their infection/vaccination status.

View Article and Find Full Text PDF

Effectiveness of Molnupiravir Treatment in Patients with COVID-19 in Korea: A Propensity Score Matched Study.

Infect Chemother

December 2023

Patient Management Team, Central Disease Control Headquarters for COVID-19, Korea Disease Control and Prevention Agency, Cheongju, Korea.

Background: The MOVe-OUT (efficacy and safety of molnupiravir [MK-4482] in non-hospitalized adult participants with COVID-19 [MK-4482-002]) trial reported that the administration of molnupiravir in unvaccinated patients with coronavirus disease 2019 (COVID-19) before the Omicron epidemic showed a preventive effect of 31% against hospitalization and death. However, studies on the preventive effect of molnupiravir against progression to severe disease and death in patients with COVID-19 during the Omicron epidemic are limited. This study aimed to evaluate the preventive effect of molnupiravir against severe/critical illness or death and death in Korean patients with COVID-19 who were vaccinated mostly during the Omicron epidemic.

View Article and Find Full Text PDF

There are limited data supporting current Centers for Disease Control and Prevention guidelines for the isolation period in moderate to severely immunocompromised patients with coronavirus disease 2019 (COVID-19). Adult COVID-19 patients who underwent solid organ transplantation (SOT) or received active chemotherapy against hematologic malignancy were enrolled and weekly respiratory samples were collected. Samples with positive genomic real-time polymerase chain reaction results underwent virus culture and rapid antigen testing (RAT).

View Article and Find Full Text PDF

Isolation and characterization of cancer-associated fibroblasts in the tumor microenvironment of hepatocellular carcinoma.

J Liver Cancer

September 2023

The Catholic University Liver Research Center and POSTECH-Catholic Biomedical Engineering Institute, College of Medicine, The Catholic University Korea, Seoul, Korea.

Background/aim: Cancer-associated fibroblasts (CAFs) play an immunosuppressive role in the tumor microenvironment (TME) of human cancers; however, their characteristics and role in hepatocellular carcinoma (HCC) remain to be elucidated.

Methods: Nine tumor and surrounding liver tissue samples from patients with HCC who underwent surgery were used to isolate patient-derived CAFs. Cell morphology was observed using an optical microscope after culture, and cell phenotypes were evaluated using flow cytometry and immunoblotting.

View Article and Find Full Text PDF

Even though the World Health Organization announced the end of the COVID-19 pandemic as a global public health emergency on May 5, 2023, SARS-CoV-2 continues to pose a significant health threat worldwide, resulting in substantial numbers of infections and fatalities. This study investigated the antiviral potential of Z-FA-FMK (FMK), a novel host cathepsin L protease inhibitor, against SARS-CoV-2 infection using both in vitro and in vivo models. In vitro assessments of FMK against a diverse set of SARS-CoV-2 strains, including the Wuhan-like strain and nine variants, demonstrated potent inhibition with EC values ranging from 0.

View Article and Find Full Text PDF